Drug intelligence / Profile preview

Saturno II

Development stage: Preclinical
Lead developer: Tarsus Pharmaceuticals
Modality: Small Molecules
Administration: Ophthalmic

Overview

Saturno II appears to refer to a drug combination or association studied for its efficacy and safety in controlling ocular inflammation following phacoemulsification (a type of cataract surgery). The available information is limited, but it is described as an "association," suggesting it may be a fixed-dose combination or co-administration of two or more agents. The precise components, mechanism of action, developer, and other details are not specified in the available sources[1].

Other names: Saturno II association

Targets

GR (Glucocorticoid receptor)TOP2A (DNA topoisomerase II)MR (Mineralocorticoid receptor)DNA gyraseTopo IV (Bacterial Topoisomerase IV)KCNH2 (Voltage-gated potassium channel subfamily H member 2)

Beyond the preview

Go deeper on Saturno II.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Saturno II.

Explore the full profile